Showing 11 of 11 recruiting trials for “Rhabdomyosarcoma”
Enrolling by InvitationNCT07449949 ↗
A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
👨⚕️ Srivandana Akshintala, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Sep 2025View details ↗
RecruitingNCT06924463 ↗
Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
👨⚕️ Alberto Pappo, MD, St. Jude Children's Research Hospital📍 3 sites📅 Started Mar 2024View details ↗
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
👨⚕️ Arhanti Sadanand, MD, University of Texas Southwestern Medical Center📍 7 sites📅 Started Apr 2023View details ↗
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →